 |
|
 |
- November 20, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Thiazolidinediones and bone biology"Prof. John Prins (biography)
English - 2007-11-10 - 29 minutes
|
 | (27 slides) |
Summary :
In this presentation Dr. Prins discusses the effects of TZDs on bone formation/resorption. Interestingly, these effects are partly caused by a TZD-induced increase in adipogenesis (1); the endocrinology of this phenomenon is discussed as well.
TZDs have an effect on many hormones including adiponectin, osteocalcin and TNF alpha. They were also shown to modulate the ratio of OPG and RANKL (2) leading to an increased activation of osteoclasts and bone resorption.
From the genetic point of view, Dr. Prins completes his presentation with some of the most recent results obtained with knockout mice (3). Some effects of TZDs on bone are beneficial and some detrimental, and it is not clear which is the major mechanism at work.
Copyright © 2008 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Regulation of progenitor cell determination (osteoblasts and adipocytes)
- Endocrinology of bone, fat and pancreas
- Effects of TZDs on bone formation/resorption
- Preclinical and genetic studies
Bibliographic references :
1. M Adams, C T Montague, J B Prins, J C Holder, S A Smith, L Sanders, J E Digby, C P Sewter, M A Lazar, V K Chatterjee and S O'Rahilly Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation J. Clin. Invest. 100(12): 3149-3153 (1997).
2. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ.Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density Cell. 1997 Apr 18;89(2):309-19.
3. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, Auwerx J.Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep. 2004 Oct;5(10):1007-12.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
